Recommendations for Benchmarking Preclinical Studies of Nanomedicines

Nanoparticle-based delivery systems provide new opportunities to overcome the limitations associated with traditional small-molecule drug therapy for cancer and to achieve both therapeutic and diagnostic functions in the same platform. Preclinical trials are generally designed to assess therapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2015-10, Vol.75 (19), p.4016-4020
Main Authors: Dawidczyk, Charlene M, Russell, Luisa M, Searson, Peter C
Format: Article
Language:English
Subjects:
Animals
Benchmarking - methods
Benchmarking - standards
Capillary Permeability
Cell Line, Tumor
Drug Carriers
Drug Delivery Systems
Drug Screening Assays, Antitumor - methods
Drug Screening Assays, Antitumor - standards
Female
Humans
Immunoconjugates - therapeutic use
Liposomes
Mice
Mice, Nude
Mice, SCID
Nanocapsules - administration & dosage
Nanomedicine - methods
Nanomedicine - standards
Nanoparticles - therapeutic use
Neoplasm Invasiveness
Neoplasms - blood supply
Neoplasms - drug therapy
Neoplasms - pathology
Research Design
Specific Pathogen-Free Organisms
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanoparticle-based delivery systems provide new opportunities to overcome the limitations associated with traditional small-molecule drug therapy for cancer and to achieve both therapeutic and diagnostic functions in the same platform. Preclinical trials are generally designed to assess therapeutic potential and not to optimize the design of the delivery platform. Consequently, progress in developing design rules for cancer nanomedicines has been slow, hindering progress in the field. Despite the large number of preclinical trials, several factors restrict comparison and benchmarking of different platforms, including variability in experimental design, reporting of results, and the lack of quantitative data. To solve this problem, we review the variables involved in the design of preclinical trials and propose a protocol for benchmarking that we recommend be included in in vivo preclinical studies of drug-delivery platforms for cancer therapy. This strategy will contribute to building the scientific knowledge base that enables development of design rules and accelerates the translation of new technologies.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-15-1558